PPIDT00364
Drug Information
| Name | Lenograstim |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB13144 |
| Type | biotech |
| Indication | The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy. Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim is also indicated to accelerate the engraftment of these cells after their reinfusion. GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome). |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous; Subcutaneous |
13000.000 IU/ml
|
| Injection, powder, for solution | Intravenous; Subcutaneous |
263 mcg
|
| Injection, powder, for solution | Intravenous; Subcutaneous |
33.6 MIU
|
| Injection, powder, for solution | Intravenous; Subcutaneous |
263 mcg/ml
|
| Injection, powder, for solution | Intravenous; Subcutaneous |
34 mIU/ml
|
| Injection, powder, lyophilized, for solution | Intravenous |
263 ug
|
| Injection, powder, for solution | Intravenous; Subcutaneous |
13 million IU/ml
|
| Injection, powder, for solution | Intravenous; Subcutaneous |
34 million IU/ml
|
| Powder | — |
100 mcg/1vial
|
| Powder | — |
250 mcg/1vial
|